SecBot SecBot
8-K ·Filed Nov 5, 2026

ZTS

Zoetis Inc.
BEARISH
Impact 5/10
Horizonweeks Processed11d 17h ago SEC0001555280-26-000048
8-K Item 2.02: Earnings release
Actionable Insight ▼ Bearish

The EPS miss and continued companion animal weakness are the key negatives, partially offset by raised adjusted EPS guidance. Monitor the Q4 earnings call for commentary on companion animal demand trends and the trajectory of the cost restructuring program.

DirectionBearish
Confidencehigh
Horizonweeks

Drugs in focus

ZTS drug pipeline →

Alfaxan Multidose 4%

● Neutral Named in this 8-K
Impact
Phase
Approved (10 mg/mL); Research/Preclinical (4% formulation)
Time to market
The standard 10 mg/mL formulation is already on the market. The 4% concentrated formulation appears to be an experimental/research-stage product with no publicly disclosed regulatory submission or commercialization timeline.
Next catalyst
None dated

What to watchAlfaxan Multidose 4% has no scheduled regulatory decision or pivotal readout in the next 12 months. The standard 10 mg/mL formulation is already marketed. Watch for any FDA submission or label expansion for the 4% concentrated formulation, but none is currently visible. Zoetis's stock moves on company-wide earnings and its large dermatology/parasiticide portfolio, not on this single anesthetic product.

How the stock moved after the report

BEARISH VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$82.11
T+0 close · Nov 5, 2026 · via day close
Latest settled
+1.04%
T+5 · $82.96
Vs SPY
−2.26%
α at T+5
Next horizon
T+20
in 17d
  1. T+0 · Nov 5 $82.11entry
  2. T+1 · 11d ago −3.30%α −3.61% · $79.40
  3. T+5 · 5d ago +1.04%α −2.26% · $82.96
  4. T+7 · todayOpen
  5. T+20 · in 17d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Zoetis Q3 2026 revenue of $2.391B was slightly above the $2.30B consensus, but GAAP net income fell 18% YoY to $591M and GAAP diluted EPS of $1.44 missed the $1.51 consensus. The company narrowed its full-year revenue guidance and raised its adjusted EPS guidance, reflecting ongoing pressure in companion animal markets offset by livestock growth.

Key Financial Metrics

EPS
$1.44
est $1.51 · -4.6%
Revenue
$2.4B
est $2.3B · +4.0% · -1.0% YoY
Rating
in line
Guidance
$9.220B-$9.320B
raised

Key Facts

  • Q3 2026 revenue $2.391B, down 1% YoY reported and organic operational
  • GAAP diluted EPS $1.44, down 12% YoY, missing consensus of $1.51
  • Adjusted diluted EPS $1.75, up 3% reported and 1% organic operational
  • U.S. segment revenue down 6% YoY; International up 4%
  • Companion animal revenue declined 5% YoY; Livestock grew 7%
  • Full-year 2026 revenue guidance narrowed to $9.220B-$9.320B (organic operational growth -2% to -1%)
  • Full-year 2026 adjusted diluted EPS guidance raised to $6.25-$6.35 from $6.15-$6.25
  • GAAP net income $591M, down 18% YoY; adjusted net income $720M, down 5%
  • Q3 included $129M in purchase accounting, acquisition/divestiture costs and certain significant items

Financial Impact

Revenue $2.391B vs consensus $2.30B; GAAP EPS $1.44 vs consensus $1.51; adjusted EPS $1.75 vs prior year $1.70

revenueepsnet incomeguidance

Segment Breakdown

SegmentRevenueGrowth
U.S.$1.2B-6.0%
International$1.1B+4.0%

Risk Factors

  • Persistent macro-driven price sensitivity and competitive pressure in companion animal dermatology and parasiticide markets
  • Generic competition impacting key brands (Cerenia, Convenia)
  • Restructuring charges and asset impairments totaling $133M in Q3 may signal ongoing operational challenges
  • U.S. segment revenue declining 6% YoY with companion animal down 8%

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
41% bullish (22 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001555280-26-000048
Document: zts-20261105.htm0001555280-26-000048
Document: 0001555280-26-000048-index-headers.html0001555280-26-000048
Document: 0001555280-26-000048-index.html0001555280-26-000048
Document: 0001555280-26-000048.txt0001555280-26-000048
8-K Data (Synthetic)0001555280-26-000048

Track record

10 reports on ZTS

Performance horizon

4 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +38.10% at T+60 after the Feb 27, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 5, 202611d ago 8-K Bearish 5/10 Viewing Entry $82.11 to $79.40 Now $84.39 −2.78% ▲ +3.30% +3.61% vs SPY
  2. Oct 16, 20264w ago Institutional Cluster Bullish 4/10 Entry $79.52 to $79.96 Now $84.39 +6.13% ▲ +0.55% +0.22% vs SPY
  3. Oct 13, 20264w ago 8-K Neutral 2/10 Entry $74.30 to $75.29 Now $84.39 +13.58% ▲ +1.33% +2.41% vs SPY
  4. Oct 8, 20265w ago 8-K Neutral 2/10 Entry $74.81 to $75.65 Now $84.39 +12.81% ▲ +1.12% +1.18% vs SPY
  5. Aug 6, 202614w ago 8-K Bearish 7/10 Entry $77.05 to $72.36 Now $84.39 −9.53% ▲ +6.09% +6.70% vs SPY
  6. May 20, 202625w ago 8-K Neutral 2/10 Entry $79.98 to $81.17 Now $84.39 +5.52% ▲ +1.49% +1.04% vs SPY
  7. May 13, 202626w ago Insider Cluster Neutral 2/10 Entry $75.24 to $73.62 Now $84.39 +12.16% ▼ −2.15% −0.93% vs SPY
  8. May 7, 202627w ago 8-K Bearish 7/10 Entry $87.24 to $82.31 Now $84.39 +3.27% ▲ +5.65% +6.48% vs SPY
  9. Apr 8, 202631w ago DEFA14A Neutral 2/10 Entry $119.65 to $119.47 Now $84.39 −29.47% ▼ −0.15% −0.72% vs SPY
  10. Feb 27, 202637w ago Court Ruling Bearish 6/10 Entry $127.51 to $124.52 Now $84.39 +33.82% ▲ +2.35% +1.47% vs SPY
Showing 10 of 10

US Market Status

Market Closed · Opens in 9h 5m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026